- Home
- STRO vs CMPS Comparison
STRO vs CMPS Comparison
Compare STRO & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- CMPS
- Stock Information
- Founded
- STRO 2003
- CMPS 2020
- Country
- STRO United States
- CMPS United Kingdom
- Employees
- STRO N/A
- CMPS N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- CMPS Health Care
- Exchange
- STRO Nasdaq
- CMPS Nasdaq
- Market Cap
- STRO 183.9M
- CMPS 280.2M
- IPO Year
- STRO 2018
- CMPS 2020
- Fundamental
- Price
- STRO $2.12
- CMPS $4.22
- Analyst Decision
- STRO Strong Buy
- CMPS Strong Buy
- Analyst Count
- STRO 7
- CMPS 6
- Target Price
- STRO $12.14
- CMPS $33.60
- AVG Volume (30 Days)
- STRO 1.4M
- CMPS 844.1K
- Earning Date
- STRO 11-13-2024
- CMPS 10-31-2024
- Dividend Yield
- STRO N/A
- CMPS N/A
- EPS Growth
- STRO N/A
- CMPS N/A
- EPS
- STRO N/A
- CMPS N/A
- Revenue
- STRO $160,955,000.00
- CMPS N/A
- Revenue This Year
- STRO N/A
- CMPS N/A
- Revenue Next Year
- STRO N/A
- CMPS N/A
- P/E Ratio
- STRO N/A
- CMPS N/A
- Revenue Growth
- STRO 230.90
- CMPS N/A
- 52 Week Low
- STRO $2.08
- CMPS $4.00
- 52 Week High
- STRO $6.13
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- STRO 28.49
- CMPS 37.99
- Support Level
- STRO $2.66
- CMPS $4.00
- Resistance Level
- STRO $3.01
- CMPS $4.91
- Average True Range (ATR)
- STRO 0.19
- CMPS 0.26
- MACD
- STRO -0.03
- CMPS 0.04
- Stochastic Oscillator
- STRO 4.30
- CMPS 24.18
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.